Clinical Applications of Comprehensive Genomic Profiling in Advanced Non-Small-Cell Lung Cancer-A Case Series.

Autor: Tsai CM; Department of Chest Medicine, Cathay General Hospital, Taipei City 112, Taiwan.; Department of Oncology, Taipei Veterans' General Hospital, Taipei City 112, Taiwan., Lin CH; Department of Chest Medicine, Cathay General Hospital, Taipei City 112, Taiwan., Chou YY; Department of Chest Medicine, Cathay General Hospital, Taipei City 112, Taiwan., Jen HY; Department of Medical Affairs, Guardant Health AMEA, Singapore 138543, Singapore., Jain S; Department of Medical Affairs, Guardant Health AMEA, Singapore 138543, Singapore.
Jazyk: angličtina
Zdroj: Current oncology (Toronto, Ont.) [Curr Oncol] 2024 May 31; Vol. 31 (6), pp. 3161-3176. Date of Electronic Publication: 2024 May 31.
DOI: 10.3390/curroncol31060239
Abstrakt: Background: Advanced non-small-cell lung cancer (NSCLC) can be treated with novel targeted therapies that are tailored to the genetic characteristics of malignancy. While tissue-based genomic testing is considered the gold standard for the detection of oncogenic driver mutations, several challenges like inadequate tissue availability, the invasiveness of procuring tumors, and prolonged turnaround time of analysis are encountered. Considering these limitations, guidelines have recognized liquid biopsies using circulating cell-free DNA (cfDNA) as a useful tool to complement conventional tissue testing. Even though cfDNA next-generation sequencing (NGS) can have high sensitivity and specificity, optimal patient benefit requires the interpretation of the molecular profiling results in the context of clinical and diagnostic features to achieve the best outcomes.
Case Descriptions: In this case series, we present six patients with advanced NSCLC whose plasma or tissue biopsy samples were analyzed with commercially available comprehensive NGS assays that elucidate the role of testing at various time points in the treatment journey. In all six cases, comprehensive genomic profiling (CGP) provided clinically useful information to guide treatment decisions.
Conclusion: Adding to the existing real-world evidence, this case series reinforces that CGP-driven treatment strategies in advanced NSCLC, coupled with other available clinical information, can optimize treatment decisions.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje